Patent intelligence · US
US 11351175
Use of reboxetine to treat narcolepsy
Use of reboxetine to treat narcolepsy
Patent details — US 11351175
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 7, 2022
- Expiration
- Jun 2, 2042
- Applicant
- AXSOME THERAPEUTICS, INC.
- Claims
- 24
- CPC classes
- A61K, A61K31/5375, A61P, A61P25/02
Quick answer
US 11351175 (Use of reboxetine to treat narcolepsy) is held by AXSOME THERAPEUTICS, INC.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXSOME THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/5375, A61P, A61P25/02, A61P25/20
More from AXSOME THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12390419
Formulations of (R)-2-amino-3-phenylpropyl carbamate
granted -
US 12384743
Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
granted -
US 12370196
Pharmaceutical compositions comprising meloxicam
granted -
US 12357640
Pharmaceutical compositions comprising meloxicam
granted -
US 12357697
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12318362
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12268693
Pharmaceutical compositions comprising a tolfenamic acid
granted -
US 12263145
Methods of administering solriamfetol to lactating women
granted
Frequently asked questions
What is US patent 11351175?
US 11351175 (Use of reboxetine to treat narcolepsy) is held by AXSOME THERAPEUTICS, INC.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11351175?
AXSOME THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 162 pharmaceutical patents for this assignee.
When does US 11351175 expire?
Our index shows an expiration date of Jun 2, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.